Article: Comparison of Metformin and Nicotinamide Riboside in Reducing Tissue Aging: Preclinical Findings

PrevNext
Healthy Aging & Longevity Preclinical

Comparison of Metformin and Nicotinamide Riboside in Reducing Tissue Aging: Preclinical Findings

Synopsis

Metformin (MET) and nicotinamide riboside (NR) both have potential anti-aging effects, but how they work in different tissues isn't fully clear. This study showed that MET and NR reduce signs of aging in human stem cells grown in the lab. In aged rats, both treatments lessened inflammation, fibrosis, and abnormal protein buildup in multiple organs. They also partially reversed age-related gene changes. Together, these results show that MET and NR can reduce aging features in cells and tissues, supporting their potential as anti-aging treatments.

Journal

Life Medicine

Share

Read more

Kidney Disease

Nicotinamide Riboside Prevents Low Kidney Nephron Numbers Caused by Maternal Protein Restriction: Preclinical Findings

SynopsisBabies born with fewer nephrons (kidney filters), often due to poor maternal nutrition, have higher risk for kidney disease and high blood pressure later. There are no current treatments to...

Read more
Cardiovascular Health

Intravenous Nicotinamide Riboside Protects the Heart from Chemotherapy-Induced Damage: Preclinical Findings

Synopsis Doxorubicin, a widely used chemotherapy drug, is effective against many cancers but often causes dose-dependent heart damage, leading to chronic heart failure. This study evaluated the ca...

Read more